As of October 27, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of Endovia Health Sciences, Inc. The largest reported stake is Devereux William T's, at 29.4%. 9 filings are on record since October 21, 2025 (Schedule 13D, October 21, 2025).
Sell to companies like Endovia Health Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: C/M Capital Master Fund, LP · Percent: 7.2% · SCHEDULE 13G
- · Holder: Aida Aragon · Percent: 5.8% · SCHEDULE 13G
- · Holder: Tong Magdalene · Percent: 7.7% · SCHEDULE 13G
- · Holder: Fore Thomas Butler · Percent: 23.7% · SCHEDULE 13D
- · Holder: Nistico Robert · Percent: 7.1% · SCHEDULE 13D
Endovia Health Sciences, Inc. has 9 Schedule 13D or 13G filings on record since 2025-10-21. 9 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 29.4% | 1,005,000 | SCHEDULE 13D, 2025-10-21 | 2025-07-31 | |
| 28.6% | 907,979 | SCHEDULE 13D, 2025-10-21 | 2025-07-31 | |
| 24.1% | 767,500 | SCHEDULE 13D, 2025-10-21 | 2025-07-31 | |
| 23.8% | 752,500 | SCHEDULE 13D, 2025-10-21 | 2025-07-31 | |
| 23.7% | 750,000 | SCHEDULE 13D, 2025-10-31 | 2025-07-31 | |
| 7.7% | 200,000 | SCHEDULE 13G, 2025-10-31 | 2025-07-31 | |
| C/M Capital Master Fund, LP | 7.2% | 797,592 | SCHEDULE 13G, 2026-10-22 | 2026-10-15 |
| 7.1% | 180,470 | SCHEDULE 13D, 2025-10-27 | 2025-07-31 | |
| 5.8% | 150,000 | SCHEDULE 13G, 2025-11-06 | 2025-07-31 |
Holding shares or following this stake? See who's behind Endovia Health Sciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Endovia Health Sciences, Inc. and the records around it.
Endovia Health Sciences, Inc. elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- C/M Capital Master Fund, LP also filed stake reports on 8 other companies: Catheter Precision, Inc. (Aug 2026), Volato Group, Inc. (Jul 2026), Beeline Holdings, Inc. (Jun 2026)
Watch Endovia Health Sciences, Inc.
Get an email when Endovia Health Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Endovia Health Sciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Endovia Health Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Endovia Health Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Meissner William R.
The Reporting Person is the President and Chief Marketing Officer of the Issuer. He acquired all of his securities with the purpose of exercising control.Item 4 of the SCHEDULE 13D filed 2025-10-21
Yorke Justin W
The Reporting Person is a director of the Issuer. He acquired all of his securities with the purpose of exercising control.Item 4 of the SCHEDULE 13D filed 2025-10-21
Caple Frederick William
The Reporting Person is a director of the Issuer. He acquired all of his securities with the purpose of exercising control.Item 4 of the SCHEDULE 13D filed 2025-10-21
Devereux William T
The Reporting Person is the Chief Financial Officer of the Issuer. He acquired all of his securities in connection with his employment. As Chief Financial Officer, he is deemed to be an affiliate as that term is defined under the Securities Act of 1933.Item 4 of the SCHEDULE 13D filed 2025-10-21
Nistico Robert
The Reporting Person is the Chief Executive Officer and Chairman of the Board of Directors of the Issuer. He acquired all of his securities with the purpose of exercising control.Item 4 of the SCHEDULE 13D filed 2025-10-27
Fore Thomas Butler
The Reporting Person is a director of the Issuer. He acquired all of his securities with the purpose of exercising control.Item 4 of the SCHEDULE 13D filed 2025-10-31
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-21 | Meissner William R. | 23.8% | SCHEDULE 13D |
| 2025-10-21 | Yorke Justin W | 28.6% | SCHEDULE 13D |
| 2025-10-21 | Caple Frederick William | 24.1% | SCHEDULE 13D |
| 2025-10-21 | Devereux William T | 29.4% | SCHEDULE 13D |
| 2025-10-27 | Nistico Robert | 7.1% | SCHEDULE 13D |
| 2025-10-31 | Tong Magdalene | 7.7% | SCHEDULE 13G |
| 2025-10-31 | Fore Thomas Butler | 23.7% | SCHEDULE 13D |
| 2025-11-06 | Aida Aragon | 5.8% | SCHEDULE 13G |
| 2026-10-22 | C/M Capital Master Fund, LP | 7.2% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Endovia Health Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.